Anaphylactic Shock Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

ARS Pharmaceuticals announces FDA acceptance of NDA for neffy ® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved SAN DIEGO– October 21, 2022– ARS Pharmaceuticals, Inc. announced today that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 21, 2022 Category: Pharmaceuticals Source Type: clinical trials

Relevance of the Self-assessment of Skills for Self-administration of Adrenaline by Auto-injectors in Patients at Risk of Severe Anaphylactic Reaction (PacAdr é)
Condition:   Severe Anaphylactic Reaction, Self-administration, Adrenaline, Self-assessment Intervention:   Sponsor:   University Hospital, Grenoble Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 3, 2022 Category: Research Source Type: clinical trials